Shopping Cart 0
Cart Subtotal
AED 0

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 7340

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 22020
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline Review, H2 2017, provides an overview of the Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline landscape.

Renal anemia is a disease in which the patient has an unusually low count of red blood cells. Renal is a term that means of the kidneys, so anemia is often associated with kidney disease. This type of anemia is caused by a lack of erythropoietin, a protein produced in the kidneys that helps to create red blood cells. Symptoms caused by renal anemia include pale skin and gums, become short of breath, dizziness and inability to think clearly.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Anemia in Chronic Kidney Disease (Renal Anemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 15, 5, 2, 7, 1 and 1 respectively.

Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders).

The pipeline guide reviews pipeline therapeutics for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Anemia in Chronic Kidney Disease (Renal Anemia)-Overview

Anemia in Chronic Kidney Disease (Renal Anemia)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Anemia in Chronic Kidney Disease (Renal Anemia)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Anemia in Chronic Kidney Disease (Renal Anemia)-Companies Involved in Therapeutics Development

3SBio Inc

Aevi Genomic Medicine Inc

Akebia Therapeutics Inc

Amgen Inc

Bayer AG

Betta Pharmaceuticals Co Ltd

Biocad

Cadila Healthcare Ltd

CCM Duopharma Biotech Bhd

Chong Kun Dang Pharmaceutical Corp

CJ HealthCare Corp

Dong-A Socio Holdings Co Ltd

FibroGen Inc

GlaxoSmithKline Plc

Intas Pharmaceuticals Ltd

Japan Tobacco Inc

JCR Pharmaceuticals Co Ltd

Myungmoon pharmaceutical Co Ltd

Novartis AG

Panacea Biotec Ltd

Pfizer Inc

PharmaEssentia Corp

PhytoHealth Corp

Pieris Pharmaceuticals Inc

Reliance Life Sciences Pvt Ltd

Xenetic Biosciences Inc

Anemia in Chronic Kidney Disease (Renal Anemia)-Drug Profiles

BPI-5014B-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

daprodustat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

desidustat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epoetin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epoetin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epoetin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epoetin zeta biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ErepoXen-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

erythropoietin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FG-2216-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HSA-EPO-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JTZ-951-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDGN-201-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

methoxy polyethylene glycol-epoetin beta biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MMP-0101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

molidustat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-1116-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PHEP-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRS-080-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RD-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Renal Anemia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

roxadustat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SSS-06-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SSS-17-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UBI-852-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vadadustat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Anemia in Chronic Kidney Disease (Renal Anemia)-Dormant Projects

Anemia in Chronic Kidney Disease (Renal Anemia)-Discontinued Products

Anemia in Chronic Kidney Disease (Renal Anemia)-Product Development Milestones

Featured News & Press Releases

Nov 01, 2017: Notice of the Start of Japanese Phase 3 Clinical Studies of the HIF-PH Inhibitor MT-6548 in Renal Anemia

Oct 31, 2017: Astellas and FibroGen Announce Positive Topline Results from First Japan Phase 3 Trial for Roxadustat in Chronic Kidney Disease Patients with Anemia

Jul 05, 2017: Zydus starts phase II trial of ZYAN1 for treating anemia in patients with CKD

May 24, 2017: Akebia Initiates Phase 2 FO2RWARD Study of Vadadustat in Dialysis Patients with Anemia Related to Chronic Kidney Disease Hyporesponsive to Treatment with Erythropoiesis-Stimulating Agents

Mar 30, 2017: Positive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of Roxadustat for Treatment of Anemia in Chronic Kidney Disease

Mar 28, 2017: Akebia Announces Publication of Phase 2a Results for Vadadustat in Patients with Anemia Related to Chronic Kidney Disease

Nov 24, 2016: GSK starts phase III programme with daprodustat for anemia associated with chronic kidney disease

Sep 26, 2016: Akebia Announces Publication Highlighting Potential Benefits of HIF Treatments for Patients with Renal Anemia

Sep 19, 2016: Akebia Announces Publication of Phase 2b Data for Vadadustat in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease

Aug 22, 2016: Akebia Announces Publication Highlighting Need for New Solutions in Treating Dialysis Patients

Aug 09, 2016: Kissei and JCR to Initiate a Phase III Clinical Trial of a Long-Acting Erythropoiesis-Stimulating Agent (Development Code: JR-131)

Aug 08, 2016: Akebia Initiates INNO2VATE Phase 3 Program for Vadadustat in Dialysis Patients With Anemia Related to Chronic Kidney Disease

Jul 25, 2016: Astellas And Fibrogen Announce First Patient Treated In Phase 3 Studies And Positive Phase 2 Results Of Roxadustat In Patients With Chronic Kidney Disease In Japan

Jun 09, 2016: Fibrogen Announces Initiation By Astellas Of Phase 3 Clinical Study In Japan Of Roxadustat/ASP1517 For The Treatment Of Anemia Of Chronic Kidney Disease Triggering $10.0 Million Milestone Payment

May 23, 2016: Akebia Announces Positive Vadadustat Data Demonstrating No Clinically Significant Drug-Drug Interaction

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Anemia in Chronic Kidney Disease (Renal Anemia), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Anemia in Chronic Kidney Disease (Renal Anemia), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by 3SBio Inc, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Aevi Genomic Medicine Inc, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Akebia Therapeutics Inc, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Amgen Inc, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Bayer AG, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Betta Pharmaceuticals Co Ltd, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Biocad, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Cadila Healthcare Ltd, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by CCM Duopharma Biotech Bhd, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by CJ HealthCare Corp, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by FibroGen Inc, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by GlaxoSmithKline Plc, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Intas Pharmaceuticals Ltd, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Japan Tobacco Inc, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by JCR Pharmaceuticals Co Ltd, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Myungmoon pharmaceutical Co Ltd, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Novartis AG, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Panacea Biotec Ltd, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Pfizer Inc, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by PharmaEssentia Corp, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by PhytoHealth Corp, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Pieris Pharmaceuticals Inc, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Reliance Life Sciences Pvt Ltd, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Xenetic Biosciences Inc, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Dormant Projects, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Dormant Projects, H2 2017 (Contd..1), H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Discontinued Products, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

3SBio Inc

Aevi Genomic Medicine Inc

Akebia Therapeutics Inc

Amgen Inc

Bayer AG

Betta Pharmaceuticals Co Ltd

Biocad

Cadila Healthcare Ltd

CCM Duopharma Biotech Bhd

Chong Kun Dang Pharmaceutical Corp

CJ HealthCare Corp

Dong-A Socio Holdings Co Ltd

FibroGen Inc

GlaxoSmithKline Plc

Intas Pharmaceuticals Ltd

Japan Tobacco Inc

JCR Pharmaceuticals Co Ltd

Myungmoon pharmaceutical Co Ltd

Novartis AG

Panacea Biotec Ltd

Pfizer Inc

PharmaEssentia Corp

PhytoHealth Corp

Pieris Pharmaceuticals Inc

Reliance Life Sciences Pvt Ltd

Xenetic Biosciences Inc

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline Review, H2 2017, provides an overview of the Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline landscape.

Renal anemia is a disease in which the patient has an unusually low count of red blood cells. Renal is a term that means of the kidneys, so anemia is often associated with kidney disease. This type of anemia is caused by a lack of erythropoietin, a protein produced in the kidneys that helps to create red blood cells. Symptoms caused by renal anemia include pale skin and gums, become short of breath, dizziness and inability to think clearly.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Anemia in Chronic Kidney Disease (Renal Anemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 15, 5, 2, 7, 1 and 1 respectively.

Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders).

The pipeline guide reviews pipeline therapeutics for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Anemia in Chronic Kidney Disease (Renal Anemia)-Overview

Anemia in Chronic Kidney Disease (Renal Anemia)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Anemia in Chronic Kidney Disease (Renal Anemia)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Anemia in Chronic Kidney Disease (Renal Anemia)-Companies Involved in Therapeutics Development

3SBio Inc

Aevi Genomic Medicine Inc

Akebia Therapeutics Inc

Amgen Inc

Bayer AG

Betta Pharmaceuticals Co Ltd

Biocad

Cadila Healthcare Ltd

CCM Duopharma Biotech Bhd

Chong Kun Dang Pharmaceutical Corp

CJ HealthCare Corp

Dong-A Socio Holdings Co Ltd

FibroGen Inc

GlaxoSmithKline Plc

Intas Pharmaceuticals Ltd

Japan Tobacco Inc

JCR Pharmaceuticals Co Ltd

Myungmoon pharmaceutical Co Ltd

Novartis AG

Panacea Biotec Ltd

Pfizer Inc

PharmaEssentia Corp

PhytoHealth Corp

Pieris Pharmaceuticals Inc

Reliance Life Sciences Pvt Ltd

Xenetic Biosciences Inc

Anemia in Chronic Kidney Disease (Renal Anemia)-Drug Profiles

BPI-5014B-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

daprodustat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

desidustat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epoetin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epoetin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epoetin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epoetin zeta biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ErepoXen-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

erythropoietin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FG-2216-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HSA-EPO-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JTZ-951-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDGN-201-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

methoxy polyethylene glycol-epoetin beta biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MMP-0101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

molidustat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-1116-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PHEP-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRS-080-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RD-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Renal Anemia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

roxadustat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SSS-06-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SSS-17-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UBI-852-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vadadustat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Anemia in Chronic Kidney Disease (Renal Anemia)-Dormant Projects

Anemia in Chronic Kidney Disease (Renal Anemia)-Discontinued Products

Anemia in Chronic Kidney Disease (Renal Anemia)-Product Development Milestones

Featured News & Press Releases

Nov 01, 2017: Notice of the Start of Japanese Phase 3 Clinical Studies of the HIF-PH Inhibitor MT-6548 in Renal Anemia

Oct 31, 2017: Astellas and FibroGen Announce Positive Topline Results from First Japan Phase 3 Trial for Roxadustat in Chronic Kidney Disease Patients with Anemia

Jul 05, 2017: Zydus starts phase II trial of ZYAN1 for treating anemia in patients with CKD

May 24, 2017: Akebia Initiates Phase 2 FO2RWARD Study of Vadadustat in Dialysis Patients with Anemia Related to Chronic Kidney Disease Hyporesponsive to Treatment with Erythropoiesis-Stimulating Agents

Mar 30, 2017: Positive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of Roxadustat for Treatment of Anemia in Chronic Kidney Disease

Mar 28, 2017: Akebia Announces Publication of Phase 2a Results for Vadadustat in Patients with Anemia Related to Chronic Kidney Disease

Nov 24, 2016: GSK starts phase III programme with daprodustat for anemia associated with chronic kidney disease

Sep 26, 2016: Akebia Announces Publication Highlighting Potential Benefits of HIF Treatments for Patients with Renal Anemia

Sep 19, 2016: Akebia Announces Publication of Phase 2b Data for Vadadustat in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease

Aug 22, 2016: Akebia Announces Publication Highlighting Need for New Solutions in Treating Dialysis Patients

Aug 09, 2016: Kissei and JCR to Initiate a Phase III Clinical Trial of a Long-Acting Erythropoiesis-Stimulating Agent (Development Code: JR-131)

Aug 08, 2016: Akebia Initiates INNO2VATE Phase 3 Program for Vadadustat in Dialysis Patients With Anemia Related to Chronic Kidney Disease

Jul 25, 2016: Astellas And Fibrogen Announce First Patient Treated In Phase 3 Studies And Positive Phase 2 Results Of Roxadustat In Patients With Chronic Kidney Disease In Japan

Jun 09, 2016: Fibrogen Announces Initiation By Astellas Of Phase 3 Clinical Study In Japan Of Roxadustat/ASP1517 For The Treatment Of Anemia Of Chronic Kidney Disease Triggering $10.0 Million Milestone Payment

May 23, 2016: Akebia Announces Positive Vadadustat Data Demonstrating No Clinically Significant Drug-Drug Interaction

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Anemia in Chronic Kidney Disease (Renal Anemia), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Anemia in Chronic Kidney Disease (Renal Anemia), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by 3SBio Inc, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Aevi Genomic Medicine Inc, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Akebia Therapeutics Inc, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Amgen Inc, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Bayer AG, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Betta Pharmaceuticals Co Ltd, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Biocad, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Cadila Healthcare Ltd, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by CCM Duopharma Biotech Bhd, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by CJ HealthCare Corp, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by FibroGen Inc, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by GlaxoSmithKline Plc, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Intas Pharmaceuticals Ltd, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Japan Tobacco Inc, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by JCR Pharmaceuticals Co Ltd, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Myungmoon pharmaceutical Co Ltd, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Novartis AG, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Panacea Biotec Ltd, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Pfizer Inc, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by PharmaEssentia Corp, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by PhytoHealth Corp, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Pieris Pharmaceuticals Inc, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Reliance Life Sciences Pvt Ltd, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Xenetic Biosciences Inc, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Dormant Projects, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Dormant Projects, H2 2017 (Contd..1), H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

3SBio Inc

Aevi Genomic Medicine Inc

Akebia Therapeutics Inc

Amgen Inc

Bayer AG

Betta Pharmaceuticals Co Ltd

Biocad

Cadila Healthcare Ltd

CCM Duopharma Biotech Bhd

Chong Kun Dang Pharmaceutical Corp

CJ HealthCare Corp

Dong-A Socio Holdings Co Ltd

FibroGen Inc

GlaxoSmithKline Plc

Intas Pharmaceuticals Ltd

Japan Tobacco Inc

JCR Pharmaceuticals Co Ltd

Myungmoon pharmaceutical Co Ltd

Novartis AG

Panacea Biotec Ltd

Pfizer Inc

PharmaEssentia Corp

PhytoHealth Corp

Pieris Pharmaceuticals Inc

Reliance Life Sciences Pvt Ltd

Xenetic Biosciences Inc